Zobrazeno 1 - 8
of 8
pro vyhledávání: '"JL Sánchez Serrano"'
Autor:
H Alabort Ayllón, J Marco del Rio, J. M. Collado Sanz, JL Sánchez Serrano, M Sáez Garrido, B Serna Serrano, C Del Pozo Carlavilla, S Ruiz Sánchez, E Tebar Martínez, C García Gómez
Publikováno v:
Section 4: Clinical pharmacy services.
Background and importance Baricitinib is an immunosuppressive agent included as one of the therapeutic options for COVID-19 in the Spanish protocol Agencia Espanola del Medicamento y Productos Sanitarios. Aim and objectives The objective was to asses
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7e16f9f0c613d342530e8a44dc42c937
https://doi.org/10.1136/ejhpharm-2021-eahpconf.145
https://doi.org/10.1136/ejhpharm-2021-eahpconf.145
Autor:
P. Araque Arroyo, J Martinez Mayordomo, MT Gómez Lluch, JL Sánchez Serrano, C Notario Dongil, M Malañon Pardo, A Marcos de la Torre
Publikováno v:
Section 4: Clinical Pharmacy Services.
Background Antibiotic prescription has been increased over the past years. A misuse of them has led to an increasing antibiotic-resistant bacteria and side effects in patients. Thus, the goal of pharmaceutical recommendations is to avoid these import
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7dec45d54cff71685345b2b1309fae8f
https://doi.org/10.1136/ejhpharm-2019-eahpconf.217
https://doi.org/10.1136/ejhpharm-2019-eahpconf.217
Autor:
MT Gómez Lluch, B Proy Vega, JL Sánchez Serrano, P Nieto-Sandoval Martín de la Sierra, MC Conde García, C Notario Dongil
Publikováno v:
Eur J Hosp Pharm
Background New hepatitis C virus (HCV) antivirals are characterised by their efficacy (achievement of sustained viral response (SVR)) and safety with remarkable adverse drug reactions (ADR), such us hepatic decompensation, hypersensitivity reactions
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f31a1d3ba167aa5459db166f899fd03
https://doi.org/10.1136/ejhpharm-2018-eahpconf.401
https://doi.org/10.1136/ejhpharm-2018-eahpconf.401
Autor:
B Proy Vega, P. Araque Arroyo, JL Sánchez Serrano, MC Conde García, C Notario Dongil, MT Gómez Lluch
Publikováno v:
Eur J Hosp Pharm
Background Some complications described with enteral nutrition (EN) administration are metabolic and electrolyte disturbances. Purpose To review glycaemic, renal and electrolyte alterations in patients receiving EN as exclusive diet. Material and met
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::096aa6dbffc6abfc7a7d3d153bd68207
https://doi.org/10.1136/ejhpharm-2018-eahpconf.427
https://doi.org/10.1136/ejhpharm-2018-eahpconf.427
Autor:
M Heredia Benito, JC Valenzuela Gámez, JA Garcia Quiñones, B Proy Vega, MT Gómez Lluch, MC Conde García, JL Sánchez Serrano
Publikováno v:
Clinical pharmacy.
Background Management of catheter related infections (CRIs) depends on the severity, type of catheter and need to keep it. When it is documented, systemic antimicrobial therapy should be started, as antibiotics lock therapy if the central venous cath
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ca4b9ecf4d0adf62636d921a962cd66b
https://doi.org/10.1136/ejhpharm-2017-000640.57
https://doi.org/10.1136/ejhpharm-2017-000640.57
Autor:
MT Gómez Lluch, MC Conde García, JL Sánchez Serrano, J.M. Tenías Burillo, JC Valenzuela Gámez, B Proy Vega
Publikováno v:
European Journal of Hospital Pharmacy. 23:A32.1-A32
Background Since the clinical trial VIGOUR, in which the use of rofecoxib was proved to be connected to a larger number of cardiovascular accidents, an increase in cardiovascular diseases connected to the use of non-steroidal anti-inflammatory drugs
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6b6bd9e28c4d52ad531f4e130ef16d33
https://doi.org/10.1136/ejhpharm-2016-000875.72
https://doi.org/10.1136/ejhpharm-2016-000875.72
Autor:
P Nieto-Sandoval Martín de la Sierra, J Jordán Bueso, P. Araque Arroyo, JC Valenzuela Gámez, JL Sánchez Serrano, B Proy Vega
Publikováno v:
European Journal of Hospital Pharmacy. 23:A227.1-A227
Background In July 2013, the European Medicines Agency suspended the marketing authorisation of tetrazepam across the European Union due to serious cutaneous adverse drug reactions (ADR). Here we examine information described in PubMed and reported t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ebf7850d541f4dc2d23684b57c791b7e
https://doi.org/10.1136/ejhpharm-2016-000875.515
https://doi.org/10.1136/ejhpharm-2016-000875.515
Publikováno v:
Revista espanola de salud publica [Rev Esp Salud Publica] 2015 Nov-Dec; Vol. 89 (6), pp. 607-13.